Jakavi 20 mg (Ruxolitinib)
₹1,512.00 – ₹5,891.00
| Thumbnail | Tablet | Price | Quantity | |
|---|---|---|---|---|
|
|
28 Tablet/s | ₹1,512.00 | ||
|
|
56 Tablet/s | ₹2,968.00 | ||
|
|
84 Tablet/s | ₹4,368.00 | ||
|
|
112 Tablet/s | ₹5,891.00 |
Description
What is Jakavi 20 mg?
Jakavi is a medicine that contains the active substance ruxolitinib. It is available as tablets (5, 10, 15 and 20 mg).
What is Jakavi use for?
Myelofibrosis is a condition where the bone marrow becomes abnormally dense and rigid, leading to the production of immature and abnormal blood cells. Adults with this disease might experience symptoms like an enlarged spleen, fever, night sweats, bone pain, and weight loss. There are three types of myelofibrosis that can treat with Jakavi 20 mg:
- Primary myelofibrosis (also called chronic idiopathic myelofibrosis), where the cause is unknown.
- Post-polycythaemia vera myelofibrosis, which develops after a condition where too many red blood cells are produced.
- Post-essential thrombocythaemia myelofibrosis, which arises after an overproduction of platelets (the blood components that help with clotting).
Polycythaemia vera is another condition that Jakavi can treat. This disease leads to the production of too many red blood cells, which can thicken the blood, reduce blood flow to organs, and occasionally lead to blood clots. Jakavi 20 mg is an option for adults who cannot tolerate or respond to treatment with hydroxyurea.
How is Jakavi 20 mg used?
Jakavi should only be prescribed by a doctor who specializes in cancer treatment. Before starting Jakavi, your doctor will check your blood counts and continue to monitor them throughout your treatment.
For myelofibrosis, the usual starting dose is up to 20 mg twice a day, depending on your platelet count. For polycythaemia vera, the starting dose is typically 10 mg twice a day.
If your treatment isn’t working well enough, your doctor may gradually increase your dose by 5 mg, but it won’t go higher than 25 mg twice a day.
In some cases, a lower dose may need—especially if you have liver or kidney problems, or if you’re taking other medications. Your doctor might stop treatment if your platelet or white blood cell counts drop too low, or if there’s no improvement in your spleen size or symptoms after six months. For polycythaemia vera, treatment might also stop if your haemoglobin levels get too low.
Other Doses of Jakavi:
How does Jakavi work?
The active ingredient in Jakavi 20 mg, called ruxolitinib, works by blocking enzymes known as Janus kinases (JAKs). These enzymes play a role in producing and growing blood cells. In conditions like myelofibrosis and polycythaemia vera, there’s too much JAK activity, which causes the body to produce too many blood cells. These extra cells can build up in organs like the spleen, causing them to swell. Jakavi helps by blocking JAKs, which slows down the overproduction of blood cells and helps ease the symptoms of these diseases.
What is a benefit of Jakavi 20 mg?
In treating myelofibrosis, Jakavi has proven to be more effective than both a placebo and the best available treatments at reducing spleen size. In one study, 42% of patients who took Jakavi 20 mg (65 out of 155) saw a significant reduction in spleen size, compare to less than 1% of patients who were given a placebo (just 1 out of 153). In a second study, 29% of patients on Jakavi (41 out of 144) reached the target spleen size reduction, while none of the patients receiving the best available treatments achieved this result (0 out of 72).
For polycythaemia vera, Jakavi 20 mg also showed positive outcomes. After 8 months of treatment, 21% of patients taking Jakavi (23 out of 110) experienced improvement, whereas only 1% of patients on the best available treatments (1 out of 112) showed any improvement.
What is the risk associate with Jakavi?
For Myelofibrosis:
Common side effects of Jakavi 20 mg (affecting more than 1 in 10 people) include low blood platelet counts (thrombocytopenia), low red blood cell counts (anaemia), low levels of neutrophils (a type of white blood cell), urinary tract infections, bleeding, bruising, weight gain, high cholesterol levels, dizziness, headaches, and increased liver enzyme levels.
For Polycythaemia Vera:
In polycythaemia vera, the common side effects (seen in more than 1 in 10 people) are similar. These include low blood platelet counts, low red blood cell counts, bleeding, bruising, high cholesterol and triglyceride levels, dizziness, increased liver enzyme levels, and high blood pressure.
Important Note:
Jakavi 20 mg should not use by women who are pregnant or breastfeeding. For a complete list of all possible side effects and restrictions, please refer to the package leaflet.
If you need to buy Celkeran 2 mg you can purchase now our Medizpills medicine.
What measures are take to ensure the safe and effective use of Jakavi?
A comprehensive risk management plan has put in place to ensure Jakavi 20 mg is use as safely as possible. This plan includes important safety information that has been add to the product’s summary and package leaflet, providing clear guidance for both healthcare professionals and patients on how to use Jakavi safely.
To further ensure patient safety, the company that manufactures Jakavi 20 mg is continuing its main studies on myelofibrosis. They will provide yearly updates on how Jakavi 20 mg affects patients, including how long they live and how long they can go without their disease getting worse or developing into leukemia. For polycythaemia vera, the company is also extending its main study to gather long-term data on Jakavi’s safety and effectiveness.
Additional information
| Active Ingredient: | Ruxolitinib |
|---|---|
| Indication | Breast cancer |
| Manufacturer | Natco Pharma Ltd. |
| Packaging | 14 Tablets in a strip |
| Strength | 20 mg |
| Delivery Time | 6 To 15 days |
Related products
Copyright 2024 © medizpills.com
Reviews
There are no reviews yet.